Education
About Us
Working with TipRanks
Follow Us
Chemomab Therapeutics (CMMB)
NASDAQ:CMMB
CMMB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.39 - $9.84
Previous CloseN/A
Volume58.22K
Average Volume (3M)128.99K
Market Cap
$13.45M
Enterprise Value$17.37M
Total Cash (Recent Filing)$10.56M
Total Debt (Recent Filing)$292.00K
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Nov 07, 2025EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding5,191,075
10 Day Avg. Volume98,875
30 Day Avg. Volume128,991
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.29
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-645.71
Enterprise Value/Ebitda-1.23
Forecast
1Y Price Target
$29.67Price Target Upside1086.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Clinical Trial DesignFavorable regulatory feedback enables a streamlined pivotal program, positioning Chemomab for a more efficient and lower-cost pivotal study.
Drug MechanismChemomab's CM-101 is differentiated from other drugs due to its dual-acting mechanism on inflammation and fibrosis.
Regulatory ApprovalChemomab has received positive feedback from the FDA, which supports the advancement of Nebokitug into Phase 3 for primary sclerosing cholangitis.
Bears Say
Enrollment ComplicationsAvoiding a biopsy endpoint was a key objective of Chemomab's regulatory interactions. Biopsy endpoints complicate enrollment and add considerable additional cost.
Study ComplexityThe lack of a required confirmatory keeps timelines on track and reduces the overall cost.
Chemomab Therapeutics News
CMMB FAQ
What was Chemomab Therapeutics’s price range in the past 12 months?
Chemomab Therapeutics lowest stock price was $2.39 and its highest was $9.84 in the past 12 months.
What is Chemomab Therapeutics’s market cap?
Chemomab Therapeutics’s market cap is $13.45M.
When is Chemomab Therapeutics’s upcoming earnings report date?
Chemomab Therapeutics’s upcoming earnings report date is Nov 07, 2025 which is in 42 days.
How were Chemomab Therapeutics’s earnings last quarter?
Chemomab Therapeutics released its earnings results on Aug 14, 2025. The company reported -$0.016 earnings per share for the quarter, beating the consensus estimate of -$0.04 by $0.024.
Is Chemomab Therapeutics overvalued?
According to Wall Street analysts Chemomab Therapeutics’s price is currently Undervalued.
Does Chemomab Therapeutics pay dividends?
Chemomab Therapeutics does not currently pay dividends.
What is Chemomab Therapeutics’s EPS estimate?
Chemomab Therapeutics’s EPS estimate is -0.04.
How many shares outstanding does Chemomab Therapeutics have?
Chemomab Therapeutics has 5,191,075 shares outstanding.
What happened to Chemomab Therapeutics’s price movement after its last earnings report?
Chemomab Therapeutics reported an EPS of -$0.016 in its last earnings report, beating expectations of -$0.04. Following the earnings report the stock price went down -6.266%.
Which hedge fund is a major shareholder of Chemomab Therapeutics?
Currently, no hedge funds are holding shares in CMMB
Chemomab Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.67 (1086.80% Upside)
$29.67 (1086.80% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 5.3%
Last 30 Days ▲ 5.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.88%
12-Months-Change
Fundamentals
Return on Equity
-120.76%
Trailing 12-Months
Asset Growth
-23.48%
Trailing 12-Months
Company Description
Chemomab Therapeutics
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
CMMB Stock 12 Month Forecast
Average Price Target
$29.67
▲(1086.80% Upside)
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
12.02% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---